Poly-adenosine diphosphate Ribose Polymerase (PARP) inhibitors are used in maintenance therapy for ovarian cancer. They function to reduce the likelihood of cancer recurrence in patients.
Their recommended dosage can be poorly tolerated by patients, causing a discontinuation of their treatment before the recommended duration outlined in treatment guidelines.
At present in Cork University Hospital (CUH), a patient-specific dose escalation programme is employed, with administration of an initial reduced dosage and increasing towards the recommended dose as the patient better tolerates the adverse effects associated with their treatment.
It is hypothesised that initiating patients on an individualised dosage, dependent on their tolerability to treatment, has a non-inferior impact on their prognosis.
The objective of this project is to undertake a retrospective medical chart review to qualify the hypothesis that an individualised dosing and scheduling programme for PARP inhibitor therapy has a non-inferior impact on patient prognosis.
